163 related articles for article (PubMed ID: 20472553)
1. Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta.
Lee WY; Hampson P; Coulthard L; Ali F; Salmon M; Lord JM; Scheel-Toellner D
J Biol Chem; 2010 Jul; 285(31):23889-98. PubMed ID: 20472553
[TBL] [Abstract][Full Text] [Related]
2. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC.
Hampson P; Chahal H; Khanim F; Hayden R; Mulder A; Assi LK; Bunce CM; Lord JM
Blood; 2005 Aug; 106(4):1362-8. PubMed ID: 15845901
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.
Benhadji KA; Serova M; Ghoul A; Cvitkovic E; Le Tourneau C; Ogbourne SM; Lokiec F; Calvo F; Hammel P; Faivre S; Raymond E
Br J Cancer; 2008 Dec; 99(11):1808-15. PubMed ID: 19034280
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).
Hampson P; Wang K; Milverton L; Ersvaer E; Bruserud O; Lord JM
Apoptosis; 2010 Aug; 15(8):946-55. PubMed ID: 20467815
[TBL] [Abstract][Full Text] [Related]
5. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.
Serova M; Ghoul A; Benhadji KA; Faivre S; Le Tourneau C; Cvitkovic E; Lokiec F; Lord J; Ogbourne SM; Calvo F; Raymond E
Mol Cancer Ther; 2008 Apr; 7(4):915-22. PubMed ID: 18413805
[TBL] [Abstract][Full Text] [Related]
6. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells.
Gillespie SK; Zhang XD; Hersey P
Mol Cancer Ther; 2004 Dec; 3(12):1651-8. PubMed ID: 15634659
[TBL] [Abstract][Full Text] [Related]
7. Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation.
Asada A; Zhao Y; Kondo S; Iwata M
J Biol Chem; 1998 Oct; 273(43):28392-8. PubMed ID: 9774466
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner.
Hampson P; Kavanagh D; Smith E; Wang K; Lord JM; Ed Rainger G
Cancer Immunol Immunother; 2008 Aug; 57(8):1241-51. PubMed ID: 18265980
[TBL] [Abstract][Full Text] [Related]
9. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity.
Ersvaer E; Kittang AO; Hampson P; Sand K; Gjertsen BT; Lord JM; Bruserud O
Toxins (Basel); 2010 Jan; 2(1):174-94. PubMed ID: 22069553
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.
Sumarni U; Reidel U; Eberle J
Cells; 2021 Apr; 10(5):. PubMed ID: 33922439
[TBL] [Abstract][Full Text] [Related]
11. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
12. Engagement of protein kinase C-theta in interferon signaling in T-cells.
Srivastava KK; Batra S; Sassano A; Li Y; Majchrzak B; Kiyokawa H; Altman A; Fish EN; Platanias LC
J Biol Chem; 2004 Jul; 279(29):29911-20. PubMed ID: 15150272
[TBL] [Abstract][Full Text] [Related]
13. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate.
Challacombe JM; Suhrbier A; Parsons PG; Jones B; Hampson P; Kavanagh D; Rainger GE; Morris M; Lord JM; Le TT; Hoang-Le D; Ogbourne SM
J Immunol; 2006 Dec; 177(11):8123-32. PubMed ID: 17114487
[TBL] [Abstract][Full Text] [Related]
14. Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.
Barrett CM; Lewis FL; Roaten JB; Sweatman TW; Israel M; Cleveland JL; Lothstein L
Mol Cancer Ther; 2002 May; 1(7):469-81. PubMed ID: 12479265
[TBL] [Abstract][Full Text] [Related]
15. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.
Olsnes AM; Ersvaer E; Ryningen A; Paulsen K; Hampson P; Lord JM; Gjertsen BT; Kristoffersen EK; Bruserud Ø
Br J Haematol; 2009 Jun; 145(6):761-74. PubMed ID: 19388934
[TBL] [Abstract][Full Text] [Related]
16. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
Le XF; Marcelli M; McWatters A; Nan B; Mills GB; O'Brian CA; Bast RC
Oncogene; 2001 Dec; 20(57):8258-69. PubMed ID: 11781840
[TBL] [Abstract][Full Text] [Related]
17. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C-theta-mediated signals enhance CD4+ T cell survival by up-regulating Bcl-xL.
Manicassamy S; Gupta S; Huang Z; Sun Z
J Immunol; 2006 Jun; 176(11):6709-16. PubMed ID: 16709830
[TBL] [Abstract][Full Text] [Related]
19. The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells.
Mason SA; Cozzi SJ; Pierce CJ; Pavey SJ; Parsons PG; Boyle GM
Invest New Drugs; 2010 Oct; 28(5):575-86. PubMed ID: 19636513
[TBL] [Abstract][Full Text] [Related]
20. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005.
Ersvaer E; Hampson P; Hatfield K; Ulvestad E; Wendelbo Ø; Lord JM; Gjertsen BT; Bruserud Ø
Cancer Immunol Immunother; 2007 Jun; 56(6):913-25. PubMed ID: 17115221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
